AIMS: To evaluate in a real-world setting the effectiveness of two drugs, orlistat and liraglutide, in patients with overweight or obesity and insufficient weight loss (WL) after a lifestyle modification programme. METHODS: Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m2 or ≥27 kg/m2 with at least a weight-related comorbidity who had failed to lose at least 5% of their weight after 6 months of lifestyle modification. The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs. RESULTS: Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included. Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase over a median follow-up period of 7 months. WL with liraglutide (-7.7 kg) was significantly greater than that observed with orlistat (-3.3 kg), and more individuals lost at least 5% of their baseline weight with liraglutide (64.7%) than with orlistat (27.4%). Rates of prediabetes significantly decreased with liraglutide in comparison to orlistat. CONCLUSIONS: In this real-world study, liraglutide showed a greater effectiveness in WL compared with orlistat and improved several obesity-associated metabolic and cardiovascular risk factors.
AIMS: To evaluate in a real-world setting the effectiveness of two drugs, orlistat and liraglutide, in patients with overweight or obesity and insufficient weight loss (WL) after a lifestyle modification programme. METHODS: Retrospective, observational cohort study comparing clinical outcomes of orlistat 120 mg three times a day and liraglutide (up to 3 mg daily) in adult patients with BMI ≥30 kg/m2 or ≥27 kg/m2 with at least a weight-related comorbidity who had failed to lose at least 5% of their weight after 6 months of lifestyle modification. The co-primary end-points, assessed at 3-6 months and at the end of the follow-up, were weight change from baseline, proportion of patients who lost at least 5% of their baseline weight and adjusted differences in WL between both drugs. RESULTS: Five hundred patients, 400 in the group of orlistat (age 47.0, weight 107.8 kg) and 100 in the group of liraglutide (age 51.9 years, weight 105.1 kg), were included. Treatment with both drugs significantly reduced weight, fasting plasma glucose, systolic BP, low-density lipoprotein-cholesterol and alanine transaminase over a median follow-up period of 7 months. WL with liraglutide (-7.7 kg) was significantly greater than that observed with orlistat (-3.3 kg), and more individuals lost at least 5% of their baseline weight with liraglutide (64.7%) than with orlistat (27.4%). Rates of prediabetes significantly decreased with liraglutide in comparison to orlistat. CONCLUSIONS: In this real-world study, liraglutide showed a greater effectiveness in WL compared with orlistat and improved several obesity-associated metabolic and cardiovascular risk factors.
Authors: Gerardo Calderon; Daniel Gonzalez-Izundegui; Kuangda L Shan; Oscar A Garcia-Valencia; Lizeth Cifuentes; Alejandro Campos; Maria L Collazo-Clavell; Meera Shah; Daniel L Hurley; Haitham S Abu Lebdeh; Mayank Sharma; Kristine Schmitz; Matthew M Clark; Karen Grothe; Manpreet S Mundi; Michael Camilleri; Barham K Abu Dayyeh; Maria D Hurtado Andrade; Mohamad A Mokadem; Andres Acosta Journal: Int J Obes (Lond) Date: 2021-11-22 Impact factor: 5.095
Authors: Sean Wharton; Christiane L Haase; Elham Kamran; Aiden Liu; Johanna Mancini; Drew Neish; Arash Pakseresht; G Sarah Power; Rebecca A G Christensen Journal: Obes Sci Pract Date: 2020-05-09
Authors: Ulf Holmbäck; Anders Forslund; Stefan Grudén; Göran Alderborn; Arvid Söderhäll; Per M Hellström; Hans Lennernäs Journal: Obes Sci Pract Date: 2020-02-07
Authors: Jung Ha Park; Ju Young Kim; Jong Han Choi; Hye Soon Park; Hyun-Young Shin; Jae Min Lee; Jin-Wook Kim; Hae-Jin Ko; Suk Chon; Bu Kyung Kim; Chul Sik Kim; Soo Lim Journal: Int J Obes (Lond) Date: 2021-01-20 Impact factor: 5.095